Lozano José Manuel, Kindelán José María, Cabello Almudena, Gonzalez Rafael, Solana Rafael, Peña José
Department of Immunology, Hospital Reina Sofía, University of Cordoba, Spain.
Int Immunopharmacol. 2006 Jun;6(6):1034-8. doi: 10.1016/j.intimp.2006.01.002. Epub 2006 Feb 3.
In order to better understand the possible beneficial effects of intermittent IL-2 treatment as complement of antiretroviral therapy in HIV-1+ patients, we have measured the levels of RANTES in the supernatants and the CD25 expression in cultured PBMCs obtained from HIV-1+ individuals in presence of IL-2. The results showed a significant increases in RANTES production and in the expression of CD25+ in the cultures with IL-2 of PBMC obtained from HIV-1+ patients with a detectable viral load in comparison with both, HIV-1+ patients with no detectable viral loads and with healthy individuals. These results suggest that therapeutic IL-2 administered in addition to highly active anti-retroviral therapy (HAART) may contribute to increase the effect of this therapy by rising both RANTES production and CD25 expression only in HIV-1+ patients with detectable viral loads.
